Collectively, these data suggest that oncogenic MYC confers a collateral stress on splicing, and that components of the spliceosome may be therapeutic entry points for aggressive MYC-driven cancers.Nature
(Fig.1n). A trend toward diminished overall survival was also found with elevatedMYCin patients with clear cell renal cancers (ccRCC;p = 0.0578) (Fig.1o). Thus, both in our preclinical models and analysis of patient datasets, we find that MYC correlates with low T-cell activation and...
Here we discover that the spliceosome is a new target of oncogenic stress in MYC-driven cancers. We identify BUD31 as a MYC-synthetic lethal gene in human mammary epithelial cells, and demonstrate that BUD31 is a component of the core spliceosome required for its assembly and catalytic ...
CANCER RESEARCH | REVIEWTargeting the SAGA and ATAC TranscriptionalCoactivator Complexes in MYC-Driven CancersLisa Maria Mustachio 1,2 , Jason Roszik 3,4 , Aimee Farria 1,2,5 , and Sharon Y.R. Dent 1,2,5ABSTRACT◥Targeting epigenetic regulators, such as histone-modifyingenzymes, provides novel...
Successful completion of this work will provide novel drug targets required for survival of aggressive MYC-amplified breast cancers.Cancer researchSydney M. MoyerNina IlicSydney GangTaylor E. ArnoffWilliam C. Hahn
The tumor suppressor protein phosphatase 2A (PP2A) is a serine/threonine phosphatase whose activity is inhibited in most human cancers. One of the best-characterized PP2A substrates is MYC proto-oncogene basic helix–loop–helix transcription factor (MYC), whose overexpression is commonly associated ...
Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers MYC can be considered to be one of the most pressing and important targets for the development of novel anti-cancer therapies. This is due to its frequent ... A D'Avola,K Kluckova,AJ Finch,... - 《Oncotargets & Therapy》 ...
A. et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13, 519–528 (2008). Article CAS PubMed PubMed Central Google Scholar Gumuskaya, B. et al. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further ...
The dependence on the mTOR–eIF4F axis has also been identified as a vulnerability in MYC-driven cancers [59–61]. A recent study discovered a novel mechanism of eukaryotic initiation factor (eIF)4F assembly in MYC-driven lymphoma that relied on ubiquitin C-terminal hydrolase (UCH)-L1, bypas...
Recently, protein arginine methyl transferase (PRMT) 5 expression has been closely associated with aberrant MYC function in various cancers, including brain tumors such as glioblastoma. However, the role of PRMT5 and its association with MYC in medulloblastoma have not been explored. Here, we ...